Anavex Life Sciences Corp (AVXL)

[nidan7500]

Grimmer is presenting during a 2-hour segment concerning Translational Treatment Strategies.
https://cslide.ctimeetingtech.com/adpd24/attendee/confcal/session/calendar?q=Anavex


© Copyright 2024

Follow InvestorsHub on Twitter! @investors_hub Like InvestorsHub on Facebook! See the latest blog posts from ADVFN on Medium!

FAQ

---------------------------------------------------------------------------------------------

[Results
The trial was successful, since the differences in the least-squares mean (LSM) change from baseline to 48
weeks between the blarcamesine and placebo groups were -1.783 [95% CI, -3.314 to -0.251]; (P = 0.0226)
for ADAS-Cog13, and -0.456 [95% CI, -0.831 to -0.080]; (P = 0.0175) for CDR-SB in patients with early AD.
In addition, validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P
= 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while
MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing
treatment to placebo.

anavex_mri.jpg

Conclusions
Among participants with early symptomatic AD, blarcamesine was generally safe, well tolerated and
significantly slowed clinical progression at 48 weeks, which is also corroborated by biomarkers from the
A/T/N spectrum, including plasma Aß42/40 ratio increase and reduction of brain atrophy in several key
regions of the brain measured by MRI.
ClinicalTrials.gov Identifier: NCT03790709./quote]